--- title: "Tango Therapeutics (TNGX) news: offering" url: "https://aibio.space/companies/tango-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TNGX offering news: Tango Therapeutics files for up to $400,000,000 at-the-market stock program. Tango Therapeutics, Inc. (NASDAQ: TNGX), United States." --- TNGX Tango Therapeutics, Inc. NASDAQ · United States # Tango Therapeutics (TNGX) news TNGX offering news Financings · 2026-08-11 ## [Tango Therapeutics files for up to $400,000,000 at-the-market stock program](https://aibio.space/news/tango-therapeutics-files-up-400-000-000-market-stock-program/) Tango Therapeutics filed to sell up to $400,000,000 of stock through Leerink Partners, replacing a $100,000,000 program of which about $64,389,566 had been sold. Its early response rates come from a small group of patients treated in combination. ## Latest Tango Therapeutics news 1. 2025-06-06 Listings [Tango Therapeutics holders approve doubling authorized shares to 400,000,000](https://aibio.space/news/tango-therapeutics-holders-approve-doubling-authorized-shares-400-000/) Common stock authorized rises from 200,000,000 shares. The vote was 85,825,060 for and 11,001,501 against, and the 8-K gives no reason for the larger share count. 2. 2025-05-12 Financings [Tango Therapeutics files $400,000,000 replacement shelf with $100,000,000 ATM supplement](https://aibio.space/news/tango-therapeutics-files-400-000-000-replacement-shelf-100-000-000-atm/) The new shelf replaces one that expires on September 12, 2025. Jefferies LLC would earn up to 3.0% on ATM sales, and Tango's stock closed at $1.10 per share on May 8, 2025. ## Tango Therapeutics at a glance - **Ticker**: TNGX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.01 billion ### Related companies - [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) NASDAQ: AXSM - [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) NASDAQ: ADPT - [Regen Biopharma](https://aibio.space/companies/regen-biopharma/) OTC: RGBP - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) NASDAQ: BDTX - [AVVAA World Health Care Products](https://aibio.space/companies/avvaa-world-health-care-products/) OTC: AVVH - [Beam Therapeutics](https://aibio.space/companies/beam-therapeutics/) NASDAQ: BEAM - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC - [Xencor](https://aibio.space/companies/xencor/) NASDAQ: XNCR ### Also on NASDAQ - [KALA BIO](https://aibio.space/companies/kala-bio/) KALA - [CollPlant Biotechnologies](https://aibio.space/companies/collplant-biotechnologies/) CLGN - [Neurocrine Biosciences](https://aibio.space/companies/neurocrine-biosciences/) NBIX - [X4 Pharmaceuticals](https://aibio.space/companies/x4-pharmaceuticals/) XFOR - [Revelation Biosciences](https://aibio.space/companies/revelation-biosciences/) REVB - [Ascendis Pharma](https://aibio.space/companies/ascendis-pharma/) ASND ## Tango Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$62.4 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | [$42.1 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | | Research and development | [$132.2 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | [$143.9 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | | Net income (loss) | [-$101.6 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | [-$130.3 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | | Cash from operations | [-$138.9 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | [-$131.5 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | | Cash and equivalents | [$112.3 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526343424/) | [$69.5 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | | Short-term investments | [$230.9 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526343424/) | [$188.4 million](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $345.6 million, plus short-term investments of $668.4 million, $1.01 billion in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Tango Therapeutics Has Tango Therapeutics raised money recently? Our latest story on this, dated Aug 11, 2026: "Tango Therapeutics files for up to $400,000,000 at-the-market stock program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tango-therapeutics-files-up-400-000-000-market-stock-program/). What is the ticker symbol of Tango Therapeutics? Tango Therapeutics, Inc. trades under the ticker TNGX on NASDAQ. Where is Tango Therapeutics listed? Tango Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Tango Therapeutics? The SEC Central Index Key (CIK) for Tango Therapeutics, Inc. is 1819133. Its filings are on SEC EDGAR. How many shares does Tango Therapeutics have outstanding? 168,610,367 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Tango Therapeutics listed under? Our directory records Tango Therapeutics, Inc. under United States. What does Tango Therapeutics do? Our directory classifies Tango Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Tango Therapeutics? The ISIN recorded for Tango Therapeutics, Inc. is US87583X1090. Does aibio.space cover Tango Therapeutics? aibio.space lists Tango Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Tango Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Tango Therapeutics's revenue last year? $62.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Tango Therapeutics profitable? Tango Therapeutics, Inc. reported a net loss of $101.6 million for the fiscal year ended Dec 31, 2025, and used $138.9 million of cash in operations, per its annual report to the SEC. How much does Tango Therapeutics spend on research and development? $132.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Tango Therapeutics have? $1.01 billion in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Tango Therapeutics (TNGX) stock news? Our latest story on Tango Therapeutics, dated Aug 11, 2026: "Tango Therapeutics files for up to $400,000,000 at-the-market stock program". Tango Therapeutics filed to sell up to $400,000,000 of stock through Leerink Partners, replacing a $100,000,000 program of which about $64,389,566 had been sold. Its early response rates come from a small group of patients treated in combination. [Source](https://aibio.space/news/tango-therapeutics-files-up-400-000-000-market-stock-program/). ## Investor discussion: Tango Therapeutics Members talk about Tango Therapeutics (TNGX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Tango Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1819133/000119312526344989/d133418d424b5.htm) 2. 2026-06-08 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1819133/000119312526261771/d151329d424b5.htm) 3. 2025-11-21 Financings Reported a financing. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1819133/000119312525290677/d941536ds3asr.htm) 4. 2025-10-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1819133/000119312525249286/d78599d424b5.htm) 5. 2025-06-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1819133/000119312525137032/d926935d8k.htm) 6. 2025-05-12 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1819133/000119312525117922/d946899ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TNGX on TradingView](https://www.tradingview.com/symbols/NASDAQ-TNGX/). ## SEC filings and registration - **SEC name**: Tango Therapeutics, Inc. - **CIK**: 1819133 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TNGX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 201 BROOKLINE AVENUE, BOSTON, MA, 02215 - **Phone**: (857) 320-4900 - **Shares outstanding**: 168,610,367 as of 2026-08-04 (10-Q filed 2026-08-11) - **Former names**: BCTG Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1819133/000119312526344997/d131656d8k.htm) filed 2026-08-11 - [424B5](https://www.sec.gov/Archives/edgar/data/1819133/000119312526344989/d133418d424b5.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/tngx-20260811.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1819133/000119312526343424/tngx-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1819133/000119312526338480/d41277d8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/d79260d8k.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1819133/000119312526266078/d81492d8k.htm) filed 2026-06-10 - [424B5](https://www.sec.gov/Archives/edgar/data/1819133/000119312526266074/d151329d424b5.htm) filed 2026-06-10 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001819133), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Tango Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TNGX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Tango Therapeutics, Inc. - **Ticker**: TNGX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US87583X1090 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TNGX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tango-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tango Therapeutics (TNGX) news: offering", 2026-10-31, https://aibio.space/companies/tango-therapeutics/